long intergenic non-protein coding RNA 1785Genealiases: []
Q-omics provides the consensus-scored LINC01785 profile across patient tissues and cancer cell-line models. LINC01785 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, LINC01785 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, LINC01785 RNA expression shows 10,477 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight BLCA, THCA, and THYM as cancer lineages where LINC01785 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01785 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01785 survival associations across molecular data types. LINC01785 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01785 RNA expression–survival associations across cancer types. High LINC01785 expression shows unfavorable associations in BLCA, LUSC, READ and SKCM, but favorable associations in UVM and HNSC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .008). Together, the overview and detailed table identify BLCA as the clearest survival context for LINC01785 RNA expression.
This table summarizes LINC01785 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01785. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01785 shows lower tumor expression in THCA, KICH, LUSC, LUAD, KIRC and COAD. The THCA box plot shows higher LINC01785 RNA expression in normal versus tumor tissue (log2 FC = −0.812, t-test p < 0.001).
This table shows molecular features associated with LINC01785 in patient tissues and cancer cell lines. In patient samples, LINC01785 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
